Teva Wins Ruling on Patents for Bendeka Cancer Drug
The Teva Pharmaceutical Industries Ltd. logo sits on a box of tablets on a pharmacy counter in this arranged photograph in London, U.K., on Thursday, Dec. 29, 2016. The rapid pace of innovation among drugmakers may continue to be overshadowed by broader investment themes, such as the switch away from defensive stocks into more cyclical industries, during 2017, according to Bloomberg Intelligence. Photographer: Chris Ratcliffe/Bloomberg
, Bloomberg
Christopher Yasiejko, Bloomberg News
(Bloomberg) -- Teva Pharmaceutical Industries Ltd. won a ruling that could keep its cancer drug Bendeka free from generic competition for more than a decade.
A federal judge in Delaware ruled proposed generic versions of Bendeka by Mylan NV, Fresenius SE’s Fresenius Kabi, closely held Apotex Inc. and Slayback Pharma LLC infringe as many as four Teva patents on the drug, which has generated more than $2 billion in sales since its 2016 launch.
©2020 Bloomberg L.P.